Bupivacaine hydrochloride, Exparel liposomal(bupivacaine)
Bupivacaine, Duocaine, Exparel, Marcaine, Sensorcaine, Vivacaine, Zynrelef (bupivacaine) is a small molecule pharmaceutical. Bupivacaine was first approved as Sensorcaine on 1982-01-01. It is used to treat postoperative pain in the USA. It has been approved in Europe to treat acute pain and postoperative pain. It is known to target G protein-activated inward rectifier potassium channel 2, A-type voltage-gated potassium channel KCND3, potassium voltage-gated channel subfamily A member 5, and sodium channel protein type 5 subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Bupivacaine, Exparel, Marcaine, Sensorcaine (discontinued: Bupivacaine, Bupivacaine liposome, Posimir, Sensorcaine, Xaracoll)
CombinationsBupivacaine epinephrine, Marcaine w/ epinephrine, Sensorcaine, Vivacaine, Zynrelef (discontinued: Bupivacaine epinephrine, Duocaine, Zynrelef)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bupivacaine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EXPAREL | Pacira BioSciences | N-022496 RX | 2011-10-28 | 2 products, RLD, RS |
Show 1 discontinued
Bupivacaine
+
Meloxicam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYNRELEF KIT | Heron Therapeutics | N-211988 RX | 2021-05-12 | 2 products, RLD, RS |
Show 1 discontinued
Bupivacaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SENSORCAINE | Fresenius Kabi | N-018304 RX | 1982-01-01 | 3 products, RLD |
| MARCAINE HYDROCHLORIDE | Hospira | N-016964 RX | 1982-01-01 | 1 products, RLD, RS |
| MARCAINE HYDROCHLORIDE PRESERVATIVE FREE | Hospira | N-016964 RX | 1982-01-01 | 1 products, RLD, RS |
| MARCAINE HYDROCHLORIDE | Hospira | N-016964 RX | 1982-01-01 | 1 products, RLD, RS |
| MARCAINE HYDROCHLORIDE PRESERVATIVE FREE | Hospira | N-016964 RX | 1982-01-01 | 2 products, RLD, RS |
| MARCAINE | Hospira | N-018692 RX | 1984-05-04 | 1 products, RLD, RS |
Show 3 discontinued
Bupivacaine hydrochloride
+
Epinephrine bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SENSORCAINE | Fresenius Kabi | N-018304 RX | 1983-09-02 | 2 products, RLD |
| MARCAINE HYDROCHLORIDE W/ EPINEPHRINE | Hospira | N-016964 RX | 1982-01-01 | 1 products, RLD, RS |
| MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE | Hospira | N-016964 RX | 1982-01-01 | 1 products, RLD, RS |
| MARCAINE HYDROCHLORIDE W/ EPINEPHRINE | Hospira | N-016964 RX | 1982-01-01 | 1 products, RLD, RS |
| MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE | Hospira | N-016964 RX | 1982-01-01 | 2 products, RLD, RS |
Show 1 discontinued
Bupivacaine hydrochloride
+
Lidocaine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUOCAINE | Amphastar Pharmaceuticals | N-021496 DISCN | 2003-05-23 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 0.25% bupivacaine hcl bupivacaine hydrochloride | ANDA | 2024-06-20 |
| blt-25 kit | unapproved drug other | 2024-09-11 |
| bupivacaine | ANDA | 2024-10-25 |
| bupivacaine hci | ANDA | 2024-01-22 |
| bupivacaine hci and epinephrine | ANDA | 2024-01-30 |
| bupivacaine hcl | New Drug Application | 2024-01-27 |
| bupivacaine hcl bupivacine hcl | ANDA | 2023-06-09 |
| bupivacaine hydrochloride | ANDA | 2025-12-18 |
| bupivacaine hydrochloride and epinephrine | ANDA | 2025-10-27 |
| bupivacaine hydrochloride bupivacaine hydrochloride and epinephrine | ANDA | 2024-10-15 |
Show 56 more
Indications
FDA
EMA
Show 11 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BUPIVACAINE, EXPAREL, PACIRA PHARMS INC | |||
| 2026-11-09 | I-929 | ||
| 2024-03-22 | NPP | ||
BUPIVACAINE / MELOXICAM, ZYNRELEF KIT, HERON THERAPS INC | |||
| 2024-05-12 | NP | ||
BUPIVACAINE, POSIMIR, INNOCOLL | |||
| 2024-02-01 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Bupivacaine, Exparel, Pacira Pharms Inc | |||
| 11033495 | 2041-01-22 | DP | U-3182 |
| 11179336 | 2041-01-22 | DP | U-3250 |
| 11278494 | 2041-01-22 | DP | U-3250 |
| 11304904 | 2041-01-22 | DP | U-3346 |
| 11311486 | 2041-01-22 | DP | U-3250 |
| 11357727 | 2041-01-22 | DP | U-3380 |
| 11426348 | 2041-01-22 | DP | U-3380 |
| 11452691 | 2041-01-22 | DP | U-3439 |
| 11819574 | 2041-01-22 | DP | U-3250 |
| 11819575 | 2041-01-22 | DP | U-3250 |
| Bupivacaine, Posimir, Innocoll | |||
| 11400019 | 2041-01-12 | DP | |
| 11771624 | 2041-01-12 | U-3724 | |
| 8153149 | 2025-09-15 | DP | |
| 8153661 | 2025-09-15 | U-3074 | |
| 8753665 | 2025-09-15 | DP | U-3074 |
| 8846072 | 2025-09-15 | DP | U-3074 |
| Bupivacaine / Meloxicam, Zynrelef Kit, Heron Theraps Inc | |||
| 11844837 | 2036-04-21 | U-3417 | |
| 9694079 | 2035-04-20 | DP | U-3118 |
| 9801945 | 2035-04-20 | DP | U-3118 |
| 10098957 | 2035-04-20 | U-3118 | |
| 10213510 | 2035-04-20 | DP | U-3118 |
| 10632199 | 2035-04-20 | DP | U-3118 |
| 10898575 | 2035-04-20 | DP | U-3118 |
| 10980886 | 2035-04-20 | DP | |
| 11083730 | 2035-04-20 | DP | U-3118 |
| 11083797 | 2035-04-20 | DP | U-3118 |
| 11413350 | 2035-04-20 | U-3417 | |
| 9592227 | 2034-03-13 | DP | U-3118 |
| 9744163 | 2034-03-13 | DP | |
| 9913909 | 2034-03-13 | U-3118 | |
| 10398686 | 2034-03-13 | DP | |
| 11253504 | 2034-03-13 | U-3118 | |
| Bupivacaine Hydrochloride, Xaracoll, Innocoll Pharms | |||
| 11746141 | 2033-01-09 | DP | |
| RE47826 | 2029-05-20 | U-2949 | |
Clinical
Clinical Trials
4303 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | — | G89.18 | 58 | 132 | 109 | 264 | 755 | 1268 |
| Pain | D010146 | EFO_0003843 | R52 | 12 | 23 | 24 | 72 | 106 | 231 |
| Analgesia | D000698 | — | — | 8 | 8 | 14 | 37 | 146 | 210 |
| Agnosia | D000377 | EFO_0007136 | F88 | 7 | 14 | 21 | 35 | 99 | 171 |
| Anesthesia | D000758 | — | — | 4 | 10 | 9 | 23 | 94 | 135 |
| Acute pain | D059787 | — | R52 | 5 | 12 | 8 | 25 | 68 | 111 |
| Spinal anesthesia | D000775 | — | — | 2 | 3 | 6 | 29 | 67 | 106 |
| Replacement arthroplasty knee | D019645 | — | — | 2 | 5 | 1 | 40 | 55 | 102 |
| Local anesthesia | D000772 | — | — | 7 | 7 | 7 | 16 | 64 | 99 |
| Anesthesia and analgesia | D000760 | — | — | 4 | 5 | 9 | 18 | 63 | 94 |
Show 388 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ganglion cysts | D045888 | — | M67.4 | 4 | 1 | 1 | — | 16 | 21 |
| Thoracotomy | D013908 | — | — | — | 1 | 1 | — | 16 | 17 |
| Cholecystitis | D002764 | — | K81 | — | — | 1 | — | 12 | 13 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 2 | — | 10 | 12 |
| Abdominal pain | D015746 | EFO_0003766 | R10.9 | — | 3 | 2 | — | 9 | 12 |
| Shoulder injuries | D000070599 | — | — | — | 1 | 1 | — | 10 | 12 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | 1 | 2 | — | 6 | 10 |
| Nephrectomy | D009392 | — | — | — | 1 | 1 | — | 9 | 10 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | 1 | — | 2 | — | 6 | 9 |
| Thyroid diseases | D013959 | — | E00-E07 | — | 2 | 2 | — | 5 | 8 |
Show 78 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Video-assisted thoracic surgery | D020775 | — | — | 2 | 2 | — | — | 28 | 31 |
| Laparoscopy | D010535 | — | — | — | 2 | — | — | 10 | 12 |
| Herniorrhaphy | D059685 | — | — | 1 | 3 | — | — | 4 | 8 |
| Laminectomy | D007796 | — | — | — | 1 | — | — | 3 | 4 |
| Postoperative cognitive complications | D000079690 | — | — | — | 1 | — | — | 3 | 4 |
| Myofibroma | D047708 | — | — | — | 1 | — | — | 3 | 4 |
| Radical mastectomy | D015409 | — | — | 2 | 2 | — | — | 2 | 4 |
| Post-traumatic headache | D051298 | — | G44.3 | 1 | 1 | — | — | 2 | 4 |
| Sarcoma | D012509 | — | — | 1 | 1 | — | — | 1 | 3 |
| Cluster headache | D003027 | — | G44.00 | — | 1 | — | — | 2 | 3 |
Show 35 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | 7 | 8 |
| Respiratory insufficiency | D012131 | — | J96.9 | 1 | — | — | — | 4 | 5 |
| Sphenopalatine ganglion block | D059387 | — | — | 1 | — | — | — | 4 | 5 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | 3 | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | — | — | — | — | 4 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | — | — | — | 2 | 3 |
| Vaginismus | D052065 | — | N94.2 | 1 | — | — | — | 1 | 2 |
| Covid-19 | D000086382 | — | U07.1 | 2 | — | — | — | — | 2 |
| Breast implantation | D019928 | — | — | 1 | — | — | — | 1 | 2 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | 1 | 2 |
Show 28 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple fractures | D000069076 | — | — | — | — | — | — | 7 | 7 |
| Congenital hip dislocation | D006618 | — | Q65.2 | — | — | — | — | 6 | 6 |
| Aortic valve stenosis | D001024 | EFO_0000266 | — | — | — | — | — | 6 | 6 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 5 | 5 |
| Acute cholecystitis | D041881 | EFO_1001289 | K81.0 | — | — | — | — | 5 | 5 |
| Acalculous cholecystitis | D042101 | EFO_1000790 | — | — | — | — | — | 5 | 5 |
| Acrodynia | D000170 | EFO_1001756 | — | — | — | — | — | 4 | 4 |
| Breast diseases | D001941 | — | N60-N65 | — | — | — | — | 4 | 4 |
| Developmental dysplasia of the hip | D000082602 | — | — | — | — | — | — | 4 | 4 |
| Pilonidal sinus | D010864 | — | L05 | — | — | — | — | 4 | 4 |
Show 269 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bupivacaine |
| INN | bupivacaine |
| Description | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide is a piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline. It is a piperidinecarboxamide, an aromatic amide and a tertiary amino compound. It is a conjugate base of a 1-butyl-2-[(2,6-dimethylphenyl)carbamoyl]piperidinium. |
| Classification | Small molecule |
| Drug class | local anesthetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C |
Identifiers
| PDB | — |
| CAS-ID | 38396-39-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1098 |
| ChEBI ID | 77431 |
| PubChem CID | 2474 |
| DrugBank | DB00297 |
| UNII ID | Y8335394RO (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCND3
KCND3
Organism
Homo sapiens
Gene name
KCND3
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily D member 3
Protein synonyms
potassium channel, voltage gated Shal related subfamily D, member 3, potassium ionic channel Kv4.3, potassium voltage-gated channel long, potassium voltage-gated channel, Shal-related subfamily, member 3, sha1-related potassium channel Kv4.3, voltage-gated K+ channel, Voltage-gated potassium channel subunit Kv4.3
Uniprot ID
Mouse ortholog
Kcnd3 (56543)
potassium voltage-gated channel subfamily D member 3 (Q9Z0V1)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Exparel – Pacira BioSciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Bupivacaine – Pacira BioSciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zynrelef – Heron Therapeutics /de/
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Bupivacaine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 30,774 documents
View more details
Safety
Black-box Warning
Black-box warning for: 0.25% bupivacaine hcl bupivacaine hydrochloride, Blt-25 kit, Bupivacaine hci, Bupivacaine hcl, Bupivacaine hcl bupivacine hcl, Bupivacaine hydrochloride, Bupivacaine hydrochloride and epinephrine, Bupivacaine hydrochloride bupivacaine hydrochloride and epinephrine, Bupivacaine hydrochloride injection, solution, Bupivilog kit, Dexlido-m kit, Dyural 40 kit, Dyural 80 kit, Dyural 80-lm, Dyural lm kit, Ketorocaine lm kit, Marbeta 25 kit, Marbeta l kit, Marcaine, Marcaine marcaine with epinephrine, Marcaine with epinephrine, Mardex 25 kit, Marlido 25 kit, Marlido kit, Marvona suik, Mlk f1 kit, Mlk f3 kit, Mlk f4 kit, Mlk kit f2, Physicians ez use m-pred, Posimir, Sensorcaine, Sensorcaine mpf, Sensorcaine sensorcaine, Sensorcaine sensorcaine-mpf sensorcaine-mpf, Sensorcaine(r) (bupivacaine hci and epinephrine), Sensorcaine-mpf, Zynrelef
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,863 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use